Cannabis & Cannabinoid Research Poster Session
Posters are available as part of the in-person conference only.
Please note the poster sessions are not eligible for Section 1 credits. Learning from poster presentations may be claimed as a scanning activity under Section 2. You may claim 0.5 credits per poster with a documented learning outcome: https://www.royalcollege.ca/rcsite/cpd/moc-
Poster Presentations
PRESENTER NAME | POSTER TITLE | PRESENTATION DATE | POSTER NUMBER |
Jessica Scheufen | How chronic vaporized cannabis exposure effects adolescent rat neurodevelopment and behaviour | Day 1 June 22 | 102 |
Yalin Sun | Decreased dopamine reactivity and elevated oxidative stress in adolescent amygdala following chronic delta9-tetrahydrocannabinol is correlated to anxiety-like and impaired social behaviours | Day 1 June 22 | 103 |
Federica Veneziani | Dissecting the cross-talk between H1R and CB1R in hypothalamic neurons in the Olanzapine-induced Metabolic Syndrome | Day 1 June 22 | 104 |
Ayat Zagzoog | The Intoxication equivalency of 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) to Δ9-tetrahydrocannabinol (THC) | Day 1 June 22 | 105 |
Helena Filippini | Effects of oral administration of delta-9-tetrahydrocannabinol on pain, anxiety, and locomotor activity in the monosodium iodoacetate (MIA) model of osteoarthritis in mice. | Day 1 June 22 | 106 |
Kenzie Halter | The in vivo intoxication equivalency of cannabigerol and ∆9- tetrahydrocannabipherol compared to ∆9- tetrahydrocannabinol | Day 1 June 22 | 107 |
Catherine Hume | Investigating how cannabis alters feeding behaviours using a rodent model of tetrahydrocannabinol (THC) vapour inhalation | Day 1 June 22 | 108 |
Sylvie Lesuis | Disruption of memory allocation by stress: a role for endocannabinoid signaling | Day 1 June 22 | 109 |
Alysha Sultan | Correlates of cannabis use disorder and cannabis use among adolescents with bipolar disorder and major depressive disorder in the National Comorbidity Survey-Adolescent Supplement (NCS-A) | Day 1 June 22 | 110 |
Erika Lozano | Stereoselective synthesis of the enantiomers of CBD | Day 1 June 22 | 111 |
Catharine Mielnik | The bidirectional effect of 2-AG on hyperdopaminergic states: implications for therapeutic 2-AG modulation in psychosis. | Day 1 June 22 | 112 |
Alan Bell | Clinical practice guidelines for cannabis and cannabinoid-based medicines in the management of chronic pain and co-occurring conditions | Day 1 June 22 | 113 |
Raesham Mahmood | Investigating the effects of nabilone on endocannabinoid metabolism in the human brain | Day 1 June 22 | 114 |
Christina Pereira | Endocannabinoid metabolism linked with alcohol use in a mixed cohort of individuals with social anxiety disorder and post traumatic stress disorder: A positron emission tomography study with [11C]CURB | Day 1 June 22 | 115 |
Claudia Poluga | Investigating endocannabinoid metabolism in cannabis use disorder: A PET study measuring fatty acid amide hydrolase during cannabis withdrawal | Day 1 June 22 | 116 |
Justyne Rodas | The effects of cannabis abstinence on clinical and cognitive outcomes in patients with co-occurring posttraumatic stress disorder and cannabis use disorder | Day 1 June 22 | 117 |
Claire Shyu | Investigating endocannabinoid metabolism in chronic pain patients with opioid use disorder: A positron emission tomography study with [C-11]CURB | Day 1 June 22 | 118 |
Maryam Sorkhou | An analysis of gender differences in cannabis use patterns in people with mental health disorders pre- and post-recreational cannabis use legalization: A repeated cross-sectional survey | Day 1 June 22 | 119 |
Hui Jue (Janet) Wang | Efficacy and safety of a novel botanical cannabinoid drug for the treatment of agitation in Alzheimer's disease: Study protocol for a multi-site, double-blind, randomized, placebo-controlled cross-over trial | Day 1 June 22 | 120 |
Savannah Lightfoot | Investigating the effects of acute vapourized THC exposure on auditory fear conditioning and fear extinction | Day 2 June 23 | 101 |
Madison Wright | A human laboratory study investigating the influence of sex on the acute pharmacological effects of a range of smoked cannabis doses | Day 2 June 23 | 102 |
Ke Bin (Kelly) Xiao | Using the Addictions Neuroclinical Assessment to assess treatment response in patients with cannabis use disorder | Day 2 June 23 | 103 |
Bhumi Bhojak | Self-reported effects of medical cannabis on illness severity, depression and anxiety in fibromyalgia patients: A large retrospective case series | Day 2 June 23 | 104 |
Bhumi Bhojak | The impact on clinical outcomes of multidisciplinary medicinal cannabis clinics on authorizing medicinal cannabis for patients suffering from anxiety | Day 2 June 23 | 105 |
Zoe Bourgault | Impact of chronic Nabilone self-administration on body weight and neural circuitry in human obesity | Day 2 June 23 | 106 |
Gwenaelle De Clifford-Faugère | Clinicians' perceptions of the risk associated with the use of medical cannabis and prescription cannabinoids for chronic pain in Quebec, Canada | Day 2 June 23 | 107 |
Sonja Elsaid | Motivations for cannabis use in individuals with Social Anxiety Disorder (SAD) | Day 2 June 23 | 108 |
Nicholas Glodosky | Chronic and acute effects of cannabis use on daily cortisol rhythms in a naturalistic environment | Day 2 June 23 | 109 |
Tanya Lazor | Factors associated with cannabis use trajectories before recreational legalization among people living with HIV in Ontario, Canada | Day 2 June 23 | 110 |
Brooke Manning | Impact of open-label medicinal cannabis use on simulation driving performance: A naturalistic study | Day 2 June 23 | 111 |
Adam Zaweel | The influence of age on driving-related cannabis effects: Exploring cannabis use frequency and related factors | Day 2 June 23 | 120 |
Bruce Crooks | What are Dalhousie medical students and residents taught about cannabis? | Day 2 June 23 | 113 |
Claudie Audet | Clinically meaningful pain relief among persons living with chronic pain using cannabis: A real-world trajectory analysis | Day 2 June 23 | 114 |
Myfanwy Graham | Regulating high potency cannabis: A narrative review of the health effects of high potency cannabis and how regulation can help | Day 2 April 22 | 115 |
Laura Best | Investigating the effects of acute intravenous alcohol administration on peripheral N-acylethanolamines and endocannabinoids: A study in heavy episodic drinking youth | Day 2 April 22 | 116 |
Marko Cavar | Potential of pharmacokinetic and pharmacodynamic interaction between cannabinoids and estrogen based combined oral contraceptives | Day 2 April 22 | 117 |
Lena Darakjian | Development of a framework to understand the impact of cannabis on hearing | Day 2 April 22 | 118 |
Patricia Di Ciano | Effects of preferred cannabis on driving in adults over the age of 65 | Day 2 April 22 | 119 |
Isaac Kuk | The influence of age on driving-related cannabis effects: Exploring cannabis use frequency and related factors | Day 2 April 22 | 120 |